BiotechTube

GR-MD-02

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psoriasis

Conditions

Psoriasis

Trial Timeline

Sep 1, 2015 → Mar 1, 2018

NCT ID
NCT02407041

About GR-MD-02

GR-MD-02 is a phase 2 stage product being developed by Galectin Therapeutics for Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02407041. Target conditions include Psoriasis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02407041Phase 2Completed

Competing Products

20 competing products in Psoriasis

See all competitors
ProductCompanyStageHype Score
Ixekizumab + PlaceboEli LillyPhase 2
52
VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + PlaceboVentyx BiosciencesPhase 2
47
LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo SubcutaneousEli LillyPhase 2
52
IxekizumabEli LillyPhase 3
77
80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + PlaceboEli LillyPhase 3
77
Placebo + BaricitinibEli LillyPhase 2
52
CT-P43 + StelaraCelltrionPhase 3
77
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
CT-P55 + EU-approved CosentyxCelltrionPhase 3
77
AMG 139AstraZenecaPhase 1
33
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
85
alefaceptAstellas PharmaPhase 2
52
Tacrolimus CreamAstellas PharmaPhase 3
77
alefaceptAstellas PharmaPhase 3
77
peficitinib + PlaceboAstellas PharmaPhase 2
52
AlefaceptAstellas PharmaPhase 3
77
Amevive exposureAstellas PharmaPre-clinical
23
alefacept + placeboAstellas PharmaPhase 3
77
alefaceptAstellas PharmaApproved
85
ASKP1240 + PlaceboAstellas PharmaPhase 2
52

Other Products from Galectin Therapeutics

belapectin + PlaceboPhase 2/3
57
GR-MD-02 + PlaceboPhase 2
44
GM-CT-01 plus 5-FluorouracilPhase 2
44
GR-MD-02 + PlaceboPhase 2
44
GM-CT-01 + 5-Fluorouracil, Leukovorin, bevacizumabPhase 2
44